(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards - 2These Are the Journalists Israel Has Killed Since the Start of the Iran War
- 3The Main 20 Gaming Control center Ever
- 4Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- 5New dinosaur tracks in Italy illustrate herds moving in unison
- Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- Best Augmented Simulation Ride: Which One Feels Generally Genuine?
- Canada Awards C$1.5 Billion Defense Contracts to L3Harris, Airbus
- 6 Eyewear Brands Worth Purchasing
- Chevron Says Damage at Wheatstone LNG Will Hamper Restart
- Wolf bites woman in a shopping area in Germany's 2nd-biggest city
- Figure out How to Pick a SUV with Senior-Accommodating Tech Elements
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- America's Confided in Cooler in 2024
